The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Korsmeyer, S. J., Wei, M. C., Saito, M., Weiler, S., Oh, K. J., & Schlesinger, P. H. (2000) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400783 · Cited by 1,034
Green, D. R. (2000) · Cell · doi:10.1016/s0092-8674(00)00003-9 · Cited by 1,008
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Yamaguchi, H., & Wang, H.-G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406933200 · Cited by 831
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-x L
Chen, C., Edelstein, L. C., & Gélinas, C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2687-2695.2000 · Cited by 760
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2833 · Cited by 664
Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane, M., Ettenberg, S. A., Nau, M. M., RUSSELL, E. K., & Lipkowitz, S. (1999) · PubMed · Cited by 551
Self-citationTumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
Ashkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
Targeting the extrinsic apoptosis pathway in cancer
Ashkenazi, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.001 · Cited by 418
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity
Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.-J., Pedersen, I. M., Kitada, S., Scott, F. L., Bailly-Maitre, B., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00332-5 · Cited by 411
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Nagane, M., Pan, G., Weddle, J. J., Dixit, V. M., Cavenee, W. K., & Huang, H. (2000) · PubMed · Cited by 387
Zhang, X. D., Franco, A., Myers, K., Gray, C. P., Nguyen, T., & Hersey, P. (1999) · PubMed · Cited by 385
Takimoto, R., & El-Deiry, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203489 · Cited by 360
Sheikh, M. S., Burns, T. F., Huang, Y., Wu, G. S., Amundson, S. A., Brooks, K., Fornace, A. J., & El‐Deiry, W. S. (1998) · PubMed · Cited by 360
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Bröcker, E. B., Krammer, P. H., & Walczak, H. (2000) · PubMed · Cited by 293
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 271
Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells
Liu, X., Yue, P., Zhou, Z., Khuri, F. R., & Sun, S.-Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh322 · Cited by 265
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F. (2000) · Biochemistry · doi:10.1021/bi992242l · Cited by 261
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
Singh, T. R., Shankar, S., Chen, X., Asim, M., & Srivastava, R. K. (2003) · PubMed · Cited by 246
Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies
Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., Smith, C. A., Goodwin, R. G., & Kubin, M. Z. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2597 · Cited by 241
Jin, Z., McDonald, E. R., Dicker, D. T., & El-Deiry, W. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405538200 · Cited by 237
Sayers, T. J., Brooks, A. D., Koh, C. Y., Ma, W., Seki, N., Raziuddin, A., Blazar, B. R., Zhang, X., Elliott, P. J., & Murphy, W. J. (2003) · Blood · doi:10.1182/blood-2002-09-2975 · Cited by 227
Taniai, M., Grambihler, A., Higuchi, H., Werneburg, N., Bronk, S. F., Farrugia, D. J., Kaufmann, S. H., & Gores, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2770 · Cited by 218
Zhang, X. D., Franco, A. V., Nguyen, T., Gray, C. P., & Hersey, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.3961 · Cited by 207
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Nimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 201
Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E., & Bhalla, K. (2000) · Blood · doi:10.1182/blood.v96.12.3900 · Cited by 196
Ganten, T. M., Haas, T. L., Sykora, J., Stahl, H., Sprick, M. R., Fas, S. C., Krueger, A., Weigand, M. A., Grosse-Wilde, A., Stremmel, W., et al. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401437 · Cited by 196
Grosse-Wilde, A., Voloshanenko, O., Bailey, S. L., Longton, G. M., Schaefer, U., Csernok, A. I., Schütz, G., Greiner, E. F., Kemp, C. J., & Walczak, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33061 · Cited by 190
p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
Liu, X., Yue, P., Khuri, F. R., & Sun, S.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1195 · Cited by 184
Chen, X., Kandasamy, K., & Srivastava, R. K. (2003) · PubMed · Cited by 183
Kim, H., Kim, E. H., Eom, Y. W., Kim, W.-H., Kwon, T. K., Lee, S. J., & Choi, K. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1568 · Cited by 181
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
Singh, T. R., Shankar, S., & Srivastava, R. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208585 · Cited by 177
Naka, T., Sugamura, K., Hylander, B. L., Widmer, M. B., Rustum, Y. M., & Repasky, E. A. (2002) · PubMed · Cited by 174
Yoshida, T., Shiraishi, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., Miki, T., & Sakai, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0693 · Cited by 173
TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells
Li, J. H., Kirkiles-Smith, N. C., McNiff, J. M., & Pober, J. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1526 · Cited by 170
van der Sloot, A. M., Tur, V., Szegezdi, E., Mullally, M. M., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510187103 · Cited by 169
Self-citationVan Geelen, C. M. M., de Vries, E. G. E., & de Jong, S. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.11.002 · Cited by 168
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Fandy, T. E., Shankar, S., Ross, D. D., Sausville, E. A., & Srivastava, R. K. (2005) · Neoplasia · doi:10.1593/neo.04655 · Cited by 156
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. W., Kennedy, D. B., Dyer, M. J. S., & Cohen, G. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401649 · Cited by 156
Shiraishi, T., Yoshida, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., Miki, T., & Sakai, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0312 · Cited by 154
Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., Zielinski, C. C., & Krainer, M. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0136 · Cited by 149
Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene
Guan, B., Yue, P., Clayman, G. L., & Sun, S. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1101 · Cited by 143
Koornstra, J. J., Kleibeuker, J. H., van Geelen, C. M. M., Rijcken, F. E. M., Hollema, H., de Vries, E. G. E., & de Jong, S. (2003) · The Journal of Pathology · doi:10.1002/path.1364 · Cited by 142
Self-citationShankar, S., Chen, X., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20126 · Cited by 130
Evdokiou, A., Bouralexis, S., Atkins, G. J., Chai, F., Hay, S., Clayer, M., & Findlay, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10376 · Cited by 129
Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q. M., von Mehren, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7422 · Cited by 123
Gong, B., & Almasan, A. (2000) · PubMed · Cited by 120
Tang, X., Sun, Y. J., Half, E., Kuo, M. T., & Sinicrope, F. A. (2002) · PubMed · Cited by 119
Voortman, J., Resende, T. P., Hassan, M., Giaccone, G., & Kruyt, F. A. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0167 · Cited by 116
Koschny, R., Ganten, T. M., Sykora, J., Haas, T. L., Sprick, M. R., Kolb, A., Stremmel, W., & Walczak, H. (2007) · Hepatology · doi:10.1002/hep.21555 · Cited by 115
Mohr, A., Lyons, M. J., Deedigan, L., Harte, T., Shaw, G., Howard, L., Barry, F., O’Brien, T., & Zwacka, R. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00317.x · Cited by 113
Shankar, S., Singh, T. R., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20069 · Cited by 112
He, Q., Huang, Y. K., & Sheikh, M. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207351 · Cited by 112
Jin, H., Yang, R., Fong, S., Tótpál, K., Lawrence, D. A., Zheng, Z., Ross, J., Koeppen, H., SCHWALL, R. H., & Ashkenazi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0408 · Cited by 109
Zhang, X. D., Gillespie, S., Borrow, J. M., & Hersey, P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00509-4 · Cited by 101
Avoiding premature apoptosis of normal epidermal cells
Qin, J., Chaturvedi, V., Bonish, B. K., & Nickoloff, B. J. (2001) · Nature Medicine · doi:10.1038/86401 · Cited by 100
Huang, Y., He, Q., Hillman, M. J., Rong, R., & Sheikh, M. S. (2001) · PubMed · Cited by 99
Pietro, R. D., Secchiero, P., Rana, R., Gibellini, D., Visani, G., Bemis, K., Zamai, L., Miscia, S., & Zauli, G. (2001) · Blood · doi:10.1182/blood.v97.9.2596 · Cited by 94
NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
Kerbauy, D. M. B., Lesnikov, V. A., Abbasi, N., Seal, S., Scott, B. L., & Deeg, H. J. (2005) · Blood · doi:10.1182/blood-2005-04-1424 · Cited by 92
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P. T., Budach, W., & Belka, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-5 · Cited by 92
Sun, S., Yue, P., Hong, W. K., & Lotan, R. (2000) · PubMed · Cited by 90
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas
An, J., Sun, Y., Fisher, M., & Rettig, M. B. (2004) · Leukemia · doi:10.1038/sj.leu.2403460 · Cited by 88
Karikari, C. A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., Welsh, K., Reed, J. C., Armour, E. P., Wong, J. W., Herman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0634 · Cited by 87
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer
McCarthy, M. M., Sznol, M., DiVito, K. A., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0158 · Cited by 85
Hao, J.-H., Yu, M., Liu, F., Newland, A. C., & Jia, L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3648 · Cited by 82
Nesterov, A., Nikrad, M. P., Johnson, T. R., & Kraft, A. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2219 · Cited by 80
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
Reesink‐Peters, N., Hougardy, B. M. T., van den Heuvel, F. A. J., ten Hoor, K. A., Hollema, H., Boezen, H. M., de Vries, E. G. E., de Jong, S., & van der Zee, A. G. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.046 · Cited by 80
Self-citationEarel, J. K., VanOosten, R. L., & Griffith, T. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3017 · Cited by 80
van Geelen, C. M. M., Westra, J. L., de Vries, E. G. E., Ek, W. B., Zwart, N., Hollema, H., Boezen, H. M., Mulder, N. H., Plukker, J. T. M., de Jong, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8809 · Cited by 71
Self-citationNimmanapalli, R., Porosnicu, M., Nguyen, D. N., Worthington, E., O’Bryan, E., Perkins, C. L., & Bhalla, K. N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1602 · Cited by 69
Tur, V., van der Sloot, A. M., Reis, C. R., Szegezdi, É., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800457200 · Cited by 67
Self-citationButler, L. M., Liapis, V., Bouralexis, S., Welldon, K. J., Hay, S. J., Thai, L. M., Labrinidis, A., Tilley, W. D., Findlay, D. M., & Evdokiou, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21939 · Cited by 66
Wirth, T., Kühnel, F., Fleischmann-Mundt, B., Woller, N., Djojosubroto, M., Rudolph, K. L., Manns, M., Zender, L., & Kubicka, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3664 · Cited by 65
Stieglmaier, J., Bremer, E., Kellner, C., Liebig, T. M., ten Cate, B., Peipp, M., Schulze‐Koops, H., Pfeiffer, M. M., Bühring, H., Greil, J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0370-8 · Cited by 62
Hougardy, B. M. T., Maduro, J. H., van der Zee, A. G. J., de Groot, D. J. A., van den Heuvel, F. A. J., de Vries, E. G. E., & de Jong, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21580 · Cited by 61
Self-citationVanOosten, R. L., Moore, J. M., Karaçay, B., & Griffith, T. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2022 · Cited by 60
Johnston, J. B., Kaboré, A. F., Strutinsky, J., Hu, X., Paul, J. T., Kropp, D. M., Kuschak, B., Begleiter, A., & Gibson, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1207004 · Cited by 59
Déjosez, M., Ramp, U., Mahotka, C., Krieg, A. H., Walczak, H., Gabbert, H. E., & Gerharz, C. D. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400746 · Cited by 58
Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines
Siervo-Sassi, R. R., Marrangoni, A., Feng, X., Naoumova, N., Winans, M. T., Edwards, R. P., & Lokshin, A. E. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00579-7 · Cited by 53
Stem cells are resistant to TRAIL receptor‐mediated apoptosis
Szegezdi, É., O’Reilly, A., Yeung, D., Vawda, R., Taylor, D. L., Murphy, M. J., Samali, A., & Mehmet, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00522.x · Cited by 50
Self-citationXiang, H., Fox, J. A., Tótpál, K., Aikawa, M., DuPree, K., Sinicropi, D. V., Lowe, J. R., & Escandón, E. (2002) · Oncogene · doi:10.1038/sj.onc.1205449 · Cited by 50
Sinicrope, F. A., & Penington, R. C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0137 · Cited by 49
Wu, X., Kakehi, Y., Mizutani, Y., Nishiyama, H., Kamoto, T., Megumi, Y., Ito, N., & Ogawa, O. (2003) · International Journal of Cancer · doi:10.1002/ijc.10948 · Cited by 48
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines
Vasilevskaya, I. A., & O'Dwyer, P. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.018 · Cited by 46
Kondo, K., Yamasaki, S., Sugie, T., Teratani, N., Kan, T., Imamura, M., & Shimada, Y. (2005) · International Journal of Cancer · doi:10.1002/ijc.21283 · Cited by 43
Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma
Arts, H., de Jong, S., Hollema, H., ten Hoor, K. A., van der Zee, A. G. J., & de Vries, E. G. E. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.054 · Cited by 39
Self-citationKang, J., Kisenge, R. R., Toyoda, H., Tanaka, S., Bu, J., Azuma, E., & Komada, Y. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04699.x · Cited by 37
Vigneswaran, N., Baucum, D. C., Wu, J. G., Lou, Y., Bouquot, J. E., Müller, S., & Zacharias, W. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-108 · Cited by 37
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Plummer, E. R., Calvert, H., Fox, N. L., Kumm, E., Jones, S. F., & Burris, H. A. (2007) · UCL Discovery (University College London) · Cited by 36
Liu, Y., Zhang, W., Cheung, L. H., Niu, T., Wu, Q., Li, C., Pelt, C. S. V., & Rosenblum, M. G. (2006) · Neoplasia · doi:10.1593/neo.06121 · Cited by 36
Chow, L. Q. M., Eckhardt, S. G., Gustafson, D. L., O’Bryant, C. L., Hariharan, S., Diab, S., Fox, N. L., Corey, A. E., Padavic, K., Brown, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2515 · Cited by 34
Functional expression of TRAIL and TRAIL‐R2 during human megakaryocytic development
Melloni, E., Secchiero, P., Celeghini, C., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20358 · Cited by 27
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
Younes, M., Georgakis, G. V., Rahmani, M., Beer, D. G., & Younes, A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.013 · Cited by 26
Wang, T. T. Y., & Jeng, J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006432201432 · Cited by 25
Cited by
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedMajor apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Kartal Yandim, M., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 582
Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions
Kavanagh, N., Ryan, E. J., Widaa, A., Sexton, G., Fennell, J., O'Rourke, S., Cahill, K. C., Kearney, C. J., O'Brien, F. J., & Kerrigan, S. W. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-17 · Cited by 547
Onto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
A magnetic switch for the control of cell death signalling in in vitro and in vivo systems
Cho, M. H., Lee, E. J., Son, M., Lee, J.-H., Yoo, D., Kim, J.-W., Park, S. W., Shin, J.-S., & Cheon, J. (2012) · Nature Materials · doi:10.1038/nmat3430 · Cited by 260
Metadata
- Authors
- Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 35
- Issue
- 3
- Pages
- 280-288
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2019276845
- Cited by
- 272
- References
- 124
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.